Background Measurement of antibody responses to polysaccharide antigens is regarded as an important assessment of an individual's ability to respond to carbohydrate antigens. The currently used assays for the measurement of pneumococcal-specific antibody use the multi-serotype vaccine Pneumovax 1 as the detection antigen.
Introduction
Infection by polysaccharide-encapsulated bacteria, such as Streptococcus pneumoniae, is associated with a signi¢cant risk of morbidity and mortality. 1 One of the main reasons for this is that these bacteria present a unique problem for the immune system. The bacteria are encapsulated within a polysaccharide capsule which both inhibits phagocytosis by macrophages and polymorphonuclear cells and induces an antibody response without the apparent involvement of T lymphocytes (T-independent type 2 antigens). These antibody responses typically have poor immunological memory, 2 are of a restricted isotype (predominantly IgM and IgG 2 ) 3 and develop late in ontogeny. 4 Those most at risk for pneumococcal infection include the very young (52 years), the elderly and immunocompromised patients. 5 The most commonly associated laboratory correlate of susceptibility has been the IgG 2 subclass concen-tration in adults. However, in children, due to the slow maturation of the IgG 2 isotype, studies have shown that IgG 1 may be a more reliable correlate of susceptibility. 6 IgG 2 has been shown to increase predominantly in response to polysaccharideencapsulated bacteria 7 and patients with de¢ciency of this subclass have been found to have an increased incidence of infection with these types of organism. 8 However, in much the same way as total serum IgG concentrations can mask subtle de¢ciencies of the IgG subclasses, IgG 2 concentrations are poor predictors of the ability to respond to polysaccharide-encapsulated bacteria, speci¢cally S. pneumoniae (unpublished data). These tests have largely been superseded by speci¢c antibody assays that measure pneumococcal-speci¢c antibody concentrations. Like all antibody measurement assays, these assays measure binding of antibody to antigen and not the functional ability of the antibody (e.g. complement activation). These assays are therefore an indirect assessment of the functional role of the antibody in protecting against pneumococcal infection.
These assays are only available in immunology laboratories with specialist interest and are predominately non-standardized enzyme-linked immunosorbent assays (ELISAs). Some work has been done on standardizing these assays; 9 an international reference preparation (PCP98-01) exists, but this has only been calibrated for IgG class-speci¢c antibodies and has not been further standardized for the IgG subclass-speci¢c antibodies. Standardized reference ranges are di¤cult to establish due to the variation in assay measurement and expression of results in a number of di¡erent arbitrary units. Therefore the assays are primarily useful to assess antibody responses following immunization 8 and are unable to predict e¡ective protection against any speci¢c serotype.
Several assumptions are made in these assays. Most assays measure the total IgG response and do not characterize the speci¢c subclass response. This assumes that the total IgG response is a true re£ection of the typical subclass-restricted response. The IgG assay is taken as an indirect measurement of the IgG 2 response. Secondly, the vaccine used for immunization, Pneumovax 1 , is commonly used as the detection antigen in most assay systems. 10 Pneumovax is a multi-serotype vaccine with 23 serotypes represented in the antigen mixture, and has been considered a convenient method of establishing the overall antibody concentration to a wide range of serotypes without the need for individual serotype assays. 11 This assumes that the measured response is a composite of individual antibody speci¢cities and correlates with the concentration of each individual serotype-speci¢c antibody in the serum. However, in a heterogeneous system such as pneumococcal polysaccharides this does not appear to be so. 12 It also assumes that all 23 serotypes have similar immunogenicity and bind to the ELISA plate with similar adsorption characteristics. Documentation to support either of these points is lacking in the literature.
An additional in£uencing factor in the measurement of pneumococcal capsule-speci¢c antibodies is the e¡ect of cell wall polysaccharide (C-polysaccharide). C-polysaccharide is a component of the pneumococcal cell wall and is distinct from the polysaccharide of the pneumococcal capsule. Antibodies to C-polysaccharide are poorly opsonic and hence do not play a signi¢cant role in protection against infection. However, C-polysaccharide is found in puri¢ed serotype-speci¢c pneumococcal capsular polysaccharide preparations and also in Pneumovax and can result in falsely elevated antibody measurements. 13 Assays that include a pre-absorption step with C-polysaccharide 14 should be used to measure only pneumococcal capsule-speci¢c polysaccharide antibodies.
This study aimed to ascertain the extent to which composite antibodyconcentrations against the mixture of the 23 pneumococcal serotypes, measured by ELISA, can predict the concentration of individual serotype-speci¢c antibodies contained within this mixture.
Materials and methods

Antigen
Pneumococcal capsular polysaccharide serotypes 3, 6B, 14 (American Type Culture Collection) and Pneumovax 1 (Merieux UK Ltd, Berkshire, UK) were used as detection antigens. A normal human serum pool (NHS), prepared from 50 healthy blood donors, with a total IgG concentration of 12 g/L was used as the standard.
Subjects and serum samples
Blood samples were taken from two non-immunized healthy adult volunteers (H1, H2) and ¢ve immunized individuals (V1^V5). All ¢ve immunized individuals had blood taken pre-immunization and 3^4 weeks post-immunization with 0.5 mL of the Pneumovax vaccine as prescribed. Ethical approval was received for immunization for the following clinical indications: diabetes and chronic obstructive airways disease. Serum samples were collected, separated within 4 h of collection and immediately stored in aliquots at 7408C until assayed.
Removal of non-speci c antibody to cell wall polysaccharide
Serum samples were diluted 1 in 100 with 0¢05% (v/v) Tween 20 in 0¢01 mmol/ L phosphate-bu¡ered saline (PBS) (Sigma, Poole, UK), incubated overnight at 48C with 1mg/mL cell wall polysaccharide (Statens Seruminstitut, Denmark) and then centrifuged for 15 min at 13 000 rpm. 14 The supernatants were assayed for pneumococcal polysaccharide antibody.
Experimental design
An equal potency ELISA assay has been used to measure pneumococcal antibody concentrations against di¡erent serotypes in absolute antibody concentrations (mg/L). The principle of equal potency assumes that any given colour signal represents the same amount of IgG irrespective of whether this is directly bound onto the plate or is antigen-bound. A sample with a known IgG concentration was directly coated onto a number of the wells of an ELISA plate. The remaining wells were coated with the bacterial capsular polysaccharide, which then captures IgG from the serum samples. Both IgG bound directly to the plate and that bound to antigen are detected with the same concentration of enzyme-linked anti-human IgG, all other conditions within the plate being identical.
To ensure a direct comparison between ELISA plates coated with di¡erent combinations of antigen, equivalent amounts of pneumococcal capsular polysaccharide must be coated onto the microtitre plates. An initial checkerboard analysis using Pneumovax as the detection antigen investigated a range of coating concentrations. An optimal coating concentration was found to be11¢5 mg/mL. In theory, as the vaccine is a mixture of 23 individual serotypes, the resultant coating concentration of each individual serotype would be approximately 0 ¢ 5 mg/mL. Therefore, a coating concentration of 0 ¢ 5 mg/mL of each individual serotype was used in all the ELISA assays.
A 96-well plate was divided into six sections. The ¢rst two columns of the plate were coated directly with doubling dilutions of the NHS to prepare a standard curve. Dilutions started at 1/10 000 and were diluted in 0¢05 mmol/ L carbonate^bicarbonate bu¡er (pH 9¢6; Sigma). The remaining ten columns were coated, in duplicate, with 0¢5 mg/mL of pneumococcal capsular polysaccharide of each serotype 3, 6B and 14, a mixture of 0¢5 mg/mL of each of the three serotypes, and 11¢5 mg/mL Pneumovax, respectively. The experiments were done within one assay plate to enable a direct comparison of the results for each of the serotype(s). All antigens were diluted with 0¢05 mmol/L carbonate^bicarbonate bu¡er; 100 mL was added to each well and incubated overnight at 48C. The plates were blocked with 0¢5% (v/v) Tween 20 in PBS for 1h at 378C. Human serum albumin (1/ 10 000 dilution of a 4¢5% w/v solution) at 100 mL/well was used as a blank control. Samples, incubated overnight at 48C with cell wall polysaccharide, were assayed at a 1/100 and 1/200 dilution with 0¢05% (v/v) Tween 20 in PBS.
A selected sample from an individual donor with a high pneumococcal antibody concentration was assayed with and without adsorption by the cell wall polysaccharide. This was used as a control for both e¤ciency of absorption and as a positive pneumococcal polysaccharide-speci¢c assay control. Interassay imprecision data gave a percentage coe¤cient of variation of 5¢4 at a concentration of 26¢6 mg/ L for the adsorbed Pneumovax ELISA.
Peroxidase-conjugated mouse anti-human IgG (Sigma) was used as the detection antibody and was diluted 1/10 000 with 0¢05% (v/v) Tween 20 in PBS. The plates were incubated overnight at 48C and then developed using 3,3 0 ,5,5 0 -tetramethylbenzidine (Sigma). Absorbances were read at 650 nm using a V max kinetic microplate reader (Molecular Devices, Crawley, UK).
Calculation of antibody mass units
A dose^response curve was made of IgG concentrations within the standard serum (NHS) directly against the optical density value and adjusted for the relevant dilution factor. Antibody concentrations of IgG bound to the polysaccharide antigens were calculated from the dose^response curve and expressed as the mean of the duplicated wells in mg/L. Sample dilutions that gave results on the linear part of the dose^response curve were used. Internal qualitycontrol samples monitored the reproducibility of the assay. Figure 1 shows the dose^response curve of total IgG directly bound to the plate. Figure 2 shows the doser esponse curve of serial dilutions of the total IgG reacting with Pneumovax. It can be seen that both curves demonstrate a comparable dose^response e¡ect over the range of dilutions covered, justifying the calculation of concentration of pneumococcal polysaccharide-speci¢c IgG. Serotype-speci¢c antibody concentrations in the NHS pool were lower and produced much shallower dose^response curves (data not shown were selected to ensure measurable antibody concentrations on the dose^response curve.
Results
The serotype-speci¢c IgG antibody concentrations against the di¡erent serotypes in the ¢ve individuals, pre-and post-immunization, and in the NHS pool are given in Table 1 .
We previously established a reference range for adults for IgG antibody concentrations measured using the Pneumovax ELISA. The median concentration of pneumococcal capsular polysaccharide IgG antibody was 7¢7 mg/L with a range of 1¢7^20¢9 mg/L. All of the individuals in this study, with the exception of individual V5, had pre-immunization concentrations within the reference range. Individual V5 had a high pre-immunization IgG antibody concentration. After immunization, four of the vaccinated individuals demonstrated an appropriate response (greater than twofold increase) against the Pneumovax vaccine; individual V5 with the higher pre-immunization concentration of antibody showed a 1¢4-fold increase post-immunization.
The results show signi¢cant di¡erences between the IgG antibody concentration against a single serotype, the mixture of the three serotypes and against Pneumovax. The increase in the concentration of antibody against the individual serotypes post immunization also varied between individuals. Three individuals had a less than 0¢5 mg/L increase in response to serotype 3. Another three individuals had a less than 0¢5 mg/L increase in response to serotype 6B. Two individuals had a less than 0¢5 mg/L increase in response to serotype 14. Individual V4 demonstrated a 25¢6 mg/ L increase of IgG antibody against Pneumovax post immunization; however, concentrations of antibody speci¢c to all three individual serotypes remained relatively unchanged. Individual V4 also had a higher concentration of IgG antibody against Pneumovax than individual V3; however, individual V3 had higher concentrations of antibody against the three individual serotypes. An antibody response against Pneumovax does not appear to represent signi¢cant responses to the serotypes investigated in this study either before or after immunization. The two unvaccinated individuals had a 2¢8-fold di¡erence between the concentrations of their IgG antibodies against Pneumovax; however, they had similar concentrations of IgG antibodies against serotype 3, serotype 14 and the three mixed serotypes. In addition, antibody concentrations measured using the Pneumovax ELISA were not proportional to the antibody concentrations measured using either single serotypes or the three mixed serotypes, again either before or after immunization. The measurement by ELISA with Pneumovax alone as antigen was unable to demonstrate serotype-speci¢c di¡erences in the antibody response.
Discussion
In the clinic, pneumococcal capsular polysaccharide antibody concentrations in individuals pre-and postpneumococcal immunization are used to indicate responses to the vaccine. It is therefore of value in evaluating antibody response to polysaccharide antigens. However, it cannot be considered an appropriate measure of protection against each of the 23 serotypes present in the Pneumovax vaccine. In this study, the immunize d individuals demonstrated adequate antibody responses against the Pneumovax vaccine, but little or no antibody response to one or more of the three investigated serotypes included in the Pneumovax vaccine.
There are a number of important factors that will a¡ect the measurement of pneumococcal capsular polysaccharide antibody in this ELISA system. Speci¢c antibody concentration measured by ELISA is based on antibody combining with its speci¢c antigen, which has been passively adsorbed on the solid phase. Polysaccharide has a low a¤nity for polystyrene 15 and coating conditions must be rigorously maintained to ensure reproducibility. The total number of epitopes available on the well surface is related to the area of the well and the coating e¤ciency of the polysaccharide. Antigen density of each serotype antigen on the surface of each well may vary due to loss, alteration or steric hindrance of antigenic epitopes and molecular size of the antigen 16 and may vary between serotypes. Finally, the coating e¤ciency of directly binding the serum to the well may di¡er from that of the binding to antigen.
ELISA assays are dependent on the a¤nity of the antibody for the detection antigen. The immunogenicity of the polysaccharides varies between serotypes so that serotype-speci¢c antibody may have di¡erent avidities and compete for antigen in the reaction vessel.
Both antigen density and avidity of antibody may, therefore, a¡ect the result of the ELISA. 17 ELISA is usually reliable when used to measure antibody responses to a single antigen. When measuring multiple speci¢cities, however, there may be limitations. In this study, we have optimiz ed our assay conditions to be able to directly compare the antibody responses to three individual serotypes, a mixture of the three serotypes and Pneumovax. The three serotypes studied were chosen because they are a frequent cause of disease, 18, 19 are the main resistant strains in Western Europe, 20 are all equal components of the Pneumovax vaccine and most importantly are structurally dissimilar.
The results of antibody concentrations against Pneumovax suggest that most patients have responded to vaccination but that this response is not re£ected in the antibody concentrations to the three individual serotypes investigated in this study. The antibody response to the mixture of the three individual serotypes demonstrated that the measured antibody concentration is related to the concentration of one or two serotypes included in the three-serotype mixture. This result further con¢rms that in a multiserotype system a response to the mixed serotype antigen may be due to a strong response to one or several serotypes. Such a measurement of a composite antibody concentration against a mixture of serotypes is a poor predictor of susceptibility against an individual serotype because it does not parallel, even approximately, the concentration against the main pathogenic serotype contained in this mixture. This raises the possibility that exposure to such a pathogenic serotype or serotypes might result in overwhelming infection despite apparently adequate antibody concentrations against Pneumovax.
Conclusion
It can be concluded that the measurement of speci¢c antibody concentration using Pneumovax can indicate the ability to respond to polysaccharide antigens, but has serious limitations when used to evaluate susceptibility to pneumococcal infection and the protective e¡ectiveness of immunization in an individual. This paper supports the previous observations that the antigen preparation used commonly in ELISA assays is not suitable for determining protective antibody concentrations in an individual, and a high titre response could mask an overall poor response. This problem has already been addressed in the USA where individual serotype-speci¢c antipneumococcal capsular polysaccharide antibodies are routinely measured. 9 
